**BAFFI ROBERT** 

Form 4

February 28, 2012

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB 3235-0287

**OMB APPROVAL** 

Number:

January 31, Expires: 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction

1(b).

(Print or Type Responses)

may continue.

| 1. Name and Address of Reporting Person * BAFFI ROBERT |   |   | 2. Issuer Name and Ticker or Trading<br>Symbol<br>BIOMARIN PHARMACEUTICAL<br>INC [BMRN] |                          |             |      |  | 5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)   |  |   |  |
|--|---|---|---|--------------------------|-------------|------|--|--|--|---|--|
| (Last)  C/O BIOM PHARMA DIGITAL                        |   | 3. Date of Earliest Transaction (Month/Day/Year) 02/24/2012 |   |                          |             |      | Director 10% Owner Security Delow) Other (specify below) EVP, Technical Operations   |  |  |   |  |
| NOVATO,  |   | Filed(Month/Day/Year)                                       |   |                          |             |      | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person |  |  |   |  |
| (City)   | (State)                                 | (Zip)   | Tab   | le I - Non               | -Derivative | Secu | rities Acqui   | red, Disposed of,  | or Beneficiall   | y Owned   |  |
| 1.Title of<br>Security<br>(Instr. 3)                   | 2. Transaction Date<br>(Month/Day/Year) |   |   | Code (Instr. 3, 4 and 5) |             |      |  | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |  |
| Common<br>Stock  | 02/24/2012                              | 02/24/201   | 12  | M                        | 16,313      | A    | \$ 6.13  | 99,806   | D  |   |  |
| Common<br>Stock  | 02/24/2012                              | 02/24/201   | 12  | M                        | 75,000      | A    | \$ 11.74   | 174,806  | D  |   |  |
| Common<br>Stock  | 02/24/2012                              | 02/24/201   | 12  | S                        | 91,313      | D    | \$<br>34.8361  | 83,493   | D  |   |  |

(1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: BAFFI ROBERT - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code<br>(Instr. 8) | 5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                    | 7. Title and Amount Underlying Securities (Instr. 3 and 4) |                                  |
|---|---|---|---|---|--|--|--------------------|--|----------------------------------|
|   |   |   |   | Code V                                  | (A) (D)  | Date Exercisable   | Expiration<br>Date | Title  | Amour<br>or<br>Number<br>of Shar |
| Stock<br>Option<br>(right to<br>buy)                | \$ 6.13   | 02/24/2012                              | 02/24/2012  | M                                       | 16,313   | 06/07/2006(2)  | 01/06/2015         | Common<br>Stock  | 16,31                            |
| Stock<br>Option<br>(right to<br>buy)<br>Common      | \$ 11.74  | 02/24/2012                              | 02/24/2012  | M                                       | 75,000   | 07/13/2006(3)  | 01/13/2016         | Common<br>Stock  | 75,00                            |

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

BAFFI ROBERT

Stock

C/O BIOMARIN PHARMACEUTICAL INC.

105 DIGITAL DRIVE

**NOVATO, CA 94949** 

**EVP**, Technical Operations

## **Signatures**

/s/ Laura Randall Woodhead,

02/28/2012

Attorney-in-Fact

Date

# \*\*Signature of Reporting Person Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

**(1)** 

Reporting Owners 2

#### Edgar Filing: BAFFI ROBERT - Form 4

The price in Column 4 is a weighted average price. The prices actually received ranged from \$34.55 to \$35.19. the reporting person will provide to the issuer, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.

- (2) Original option grant vested 6/48ths on July 7, 2005 and 1/48th on the 7th of every month thereafter.
- (3) Original option grant vested 6/48ths on July 13, 2006 and 1/48th on the 13th of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.